Cullinan Therapeutics, Inc. Cash Flow Statement

Cash Flow Statement Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Operating Activities
Net Income -59.45M-67.48M109.19M-155.10M-167.57M
Depreciation and Depletion 0.10M0.10M
Share-based Compensation 14.91M24.38M27.96M30.44M37.82M
Gains from Sales and Divestitures 0.13M0.28M0.05M
Gains from Investment Securities 4.62M9.26M9.33M-4.43M10.40M
Asset Writedowns and Impairment 0.44M
Non-cash Items 3.27M3.71M
Cash from Operations -29.77M-43.43M-126.66M-134.28M-145.30M
Depreciation, Depletion & Amortization
Depreciation & Amortization (CF) 0.06M0.05M0.09M0.31M0.31M
Change in Working Capital
Change in Account Payables 5.58M-4.83M-0.51M-0.17M-0.81M
Change in Accured Expenses 1.75M4.56M8.53M10.05M2.90M
Change in Taxes 4.28M-4.28M
Investing Activities
Capital Expenditures 0.01M1.13M0.21M
Sales of Property, Plant and Equipment 0.09M
Acquisitions -1.45M
Change in Acquisitions & Divestments 62.90M192.04M352.93M409.40M584.82M
Cash from Investing Activities -5.42M-333.77M248.97M35.81M-136.31M
Financing Activities
Other financing activities 14.91M24.38M27.96M30.44M37.82M
Debt Issuance and Repayment
Long-Term Debt Repayments 2.20M
Change in Capital Stock
Shares Issued 145.45M267.27M1.15M38.39M262.65M
Shares Repurchased 6.57M
Preferred Shares Issued 2.38M1.82M
Dividend Payments
Dividends Paid - Common 33.28M4.45M
Misc.
Cash from Financing Activities 140.14M268.78M-25.93M40.75M266.19M
Change in Cash 104.95M-108.42M96.38M-57.72M-15.43M
Free Cash Flow -29.78M-43.43M-127.80M-134.48M-145.30M
Net Cash Flow 104.95M-108.42M96.38M-57.72M-15.43M